中链甘油三酯生酮饮食在神经与代谢疾病中的作用机制
生酮饮食作为难治性癫痫的非药物治疗,其机制传统上认为依赖酮体供能。但中链脂肪酸可直接抑制AMPA受体并通过线粒体生物合成改变细胞能量学,可能比酮体更关键地阻断癫痫发作。这些机制或也涉及阿尔茨海默病神经退行性变、癌症增殖和2型糖尿病胰岛素抵抗。
要点
- 中链脂肪酸可直接抑制AMPA受体,可能比酮体更关键地提高癫痫阈值。
- 生酮饮食机制或涉及阿尔茨海默病、癌症和2型糖尿病等疾病。
- 未来研究应分析中链脂肪酸以开发新的药物和饮食疗法。
核心结论
- 中链脂肪酸而非酮体可能通过抑制AMPA受体和线粒体生物合成来阻断癫痫发作并提高癫痫阈值。
研究设计与样本
- 综述,未报告系统检索范围与样本量。
主要发现
- 酮体为脑细胞提供比葡萄糖更高效的能量源,并增加腺苷水平,可能影响癫痫控制。
- 中链脂肪酸可直接抑制AMPA受体(谷氨酸受体),并通过线粒体生物合成改变细胞能量学。
- 中链脂肪酸而非酮体可能阻断癫痫发作并提高癫痫阈值。
- 生酮饮食机制可能涉及预防阿尔茨海默病神经退行性变、癌症增殖与扩散及2型糖尿病胰岛素抵抗。
临床怎么用
- 未来生酮饮食研究应分析中链脂肪酸,以深入理解其在改良饮食中的作用。
- 相关研究结果可能促进癫痫及其他疾病的新药物和饮食疗法开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-fat, low-carbohydrate diets, known as ketogenic diets, have been used as a non-pharmacological treatment for refractory epilepsy. A key mechanism of this treatment is thought to be the generation of ketones, which provide brain cells (neurons and astrocytes) with an energy source that is more efficient than glucose, resulting in beneficial downstream metabolic changes, such as increasing adenosine levels, which might have effects on seizure control. However, some studies have challenged the central role of ketones because medium-chain fatty acids, which are part of a commonly used variation of the diet (the medium-chain triglyceride ketogenic diet), have been shown to directly inhibit AMPA receptors (glutamate receptors), and to change cell energetics through mitochondrial biogenesis. Through these mechanisms, medium-chain fatty acids rather than ketones are likely to block seizure onset and raise seizure threshold. The mechanisms underlying the ketogenic diet might also have roles in other disorders, such as preventing neurodegeneration in Alzheimer's disease, the proliferation and spread of cancer, and insulin resistance in type 2 diabetes. Analysing medium-chain fatty acids in future ketogenic diet studies will provide further insights into their importance in modified forms of the diet. Moreover, the results of these studies could facilitate the development of new pharmacological and dietary therapies for epilepsy and other disorders.
引用
- Augustin K, Khabbush A, Williams S, et al. Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders. Lancet Neurol. 2017. PMID: 29263011. doi:10.1016/S1474-4422(17)30408-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。